Skip to main content
NCBI home page
British Journal of Pharmacology logoLink to British Journal of Pharmacology
. 1987 Jun;91(2):299–306. doi: 10.1111/j.1476-5381.1987.tb10284.x

Prevention of physostigmine-induced lethality by the opioid analgesic meptazinol in the mouse.

A Bottoncetti, A Galli
PMCID: PMC1853510  PMID: 3607358

Abstract

The prophylactic action of meptazinol against physostigmine- and neostigmine-induced lethality was evaluated in mice. Meptazinol proved to be effective against physostigmine (1 mg kg-1 i.p.), but not against neostigmine (0.5 mg kg-1 i.p.). The antagonism by meptazinol of physostigmine-induced poisoning was maximal when the drug was administered 15 min before physostigmine. Under these conditions the ED50 (95% confidence limits) of meptazinol was 24 (22.0-26.1) mg kg-1 s.c. A 30 mg kg-1 dose of the drug prevented lethality in 89% of the animals. The action of meptazinol was not antagonized by naloxone hydrochloride (2 mg kg-1 i.p.), injected 10 min before meptazinol. Pretreatment of mice with 30 mg kg-1 meptazinol 15 min before physostigmine (1 mg kg-1) poisoning increased brain acetylcholinesterase (AChE) activity on average, from 8 to 31% of control values. The protection of cholinesterases against physostigmine- and neostigmine-induced inactivation was demonstrated in vitro directly on purified preparations of the enzymes using a dilution method. The ED50 values (95% confidence limits) for the protective effect of meptazinol of electric eel AChE against 1 and 3 microM physostigmine and 1 microM neostigmine were 2.6 (1.4-4.9), 9.5 (5-18) and 3 (1.6-5.7) microM, respectively, while for protection of horse serum butyrylcholinesterase (BuChE) against the same inhibitors, the ED50 values were 12 (5.4-26.4), 42 (27-65.1) and 8 (3.6-17.6) microM, respectively. It is suggested that prevention of physostigmine-induced lethality by meptazinol is a consequence of its protective action on AChE in the central nervous system.

Full text

PDF
299

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berry W. K., Davies D. R. The use of carbamates and atropine in the protection of animals against poisoning by 1,2,2-trimethylpropyl methylphosphonofluoridate. Biochem Pharmacol. 1970 Mar;19(3):927–934. doi: 10.1016/0006-2952(70)90256-x. [DOI] [PubMed] [Google Scholar]
  2. Bill D. J., Hartley J. E., Stephens R. J., Thompson A. M. The antinociceptive activity of meptazinol depends on both opiate and cholinergic mechanisms. Br J Pharmacol. 1983 May;79(1):191–199. doi: 10.1111/j.1476-5381.1983.tb10512.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Dirnhuber P., French M. C., Green D. M., Leadbeater L., Stratton J. A. The protection of primates against soman poisoning by pretreatment with pyridostigmine. J Pharm Pharmacol. 1979 May;31(5):295–299. doi: 10.1111/j.2042-7158.1979.tb13504.x. [DOI] [PubMed] [Google Scholar]
  4. Duvoisin R. C. Cholinergic-anticholinergic antagonism in parkinsonism. Arch Neurol. 1967 Aug;17(2):124–136. doi: 10.1001/archneur.1967.00470260014002. [DOI] [PubMed] [Google Scholar]
  5. ELLMAN G. L., COURTNEY K. D., ANDRES V., Jr, FEATHER-STONE R. M. A new and rapid colorimetric determination of acetylcholinesterase activity. Biochem Pharmacol. 1961 Jul;7:88–95. doi: 10.1016/0006-2952(61)90145-9. [DOI] [PubMed] [Google Scholar]
  6. Ennis C., Haroun F., Lattimer N. Can the effects of meptazinol on the guinea-pig isolated ileum be explained by inhibition of acetylcholinesterase? J Pharm Pharmacol. 1986 Jan;38(1):24–27. doi: 10.1111/j.2042-7158.1986.tb04461.x. [DOI] [PubMed] [Google Scholar]
  7. Galli A. Inhibition of cholinesterases by the opioid analgesic meptazinol. Biochem Pharmacol. 1985 May 1;34(9):1579–1581. doi: 10.1016/0006-2952(85)90703-8. [DOI] [PubMed] [Google Scholar]
  8. Galli A., Malmberg Aiello P., Renzi G., Bartolini A. In-vitro and in-vivo protection of acetylcholinesterase by eseroline against inactivation by diisopropyl fluorophosphate and carbamates. J Pharm Pharmacol. 1985 Jan;37(1):42–48. doi: 10.1111/j.2042-7158.1985.tb04928.x. [DOI] [PubMed] [Google Scholar]
  9. Gordon J. J., Leadbeater L., Maidment M. P. The protection of animals against organophosphate poisoning by pretreatment with a carbamate. Toxicol Appl Pharmacol. 1978 Jan;43(1):207–216. doi: 10.1016/s0041-008x(78)80045-3. [DOI] [PubMed] [Google Scholar]
  10. Harris L., Stitcher D. Protection against diisopropylfluorophosphate intoxication by pyridostigmine and physostigmine in combination with atropine and mecamylamine. Naunyn Schmiedebergs Arch Pharmacol. 1984 Aug;327(1):64–69. doi: 10.1007/BF00504993. [DOI] [PubMed] [Google Scholar]
  11. Holmes B., Ward A. Meptazinol. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy. Drugs. 1985 Oct;30(4):285–312. doi: 10.2165/00003495-198530040-00001. [DOI] [PubMed] [Google Scholar]
  12. Maayani S., Egozi Y., Pinchasi I., Sokolovsky M. On the interaction of drugs with the cholinergic nervous system--V. Characterization of some effects induced by physostigmine in mice: in vivo and in vitro studies. Biochem Pharmacol. 1978 Jan 15;27(2):203–211. doi: 10.1016/0006-2952(78)90302-7. [DOI] [PubMed] [Google Scholar]
  13. Main A. R., Hastings F. L. Carbamylation and binding constants for the inhibition of acetylcholinesterase by physostigmine (eserine). Science. 1966 Oct 21;154(3747):400–402. doi: 10.1126/science.154.3747.400. [DOI] [PubMed] [Google Scholar]
  14. Niemegeers C. J., Awouters F., Lenaerts F. M., Vermeire J., Janssen P. A. Prevention of physostigmine-induced lethality in rats. A pharmacological analysis. Arch Int Pharmacodyn Ther. 1982 Sep;259(1):153–165. [PubMed] [Google Scholar]
  15. Nose T., Kojima M. A simple screening method for antiparkinsonian drugs in mice. Eur J Pharmacol. 1970 Apr;10(1):83–86. doi: 10.1016/0014-2999(70)90161-5. [DOI] [PubMed] [Google Scholar]
  16. Rosecrans J. A., Domino E. F. Comparative effects of physostigmine and neostigmine on acquisition and performance of a conditioned avoidance behavior in the rat. Pharmacol Biochem Behav. 1974 Jan-Feb;2(1):67–72. doi: 10.1016/0091-3057(74)90136-1. [DOI] [PubMed] [Google Scholar]
  17. Singh A. K., Zeleznikar R. J., Jr, Drewes L. R. Protection from quinidine or physostigmine against in vitro inhibition by sarin of acetylcholinesterase activity. Life Sci. 1986 Jan 13;38(2):165–172. doi: 10.1016/0024-3205(86)90008-1. [DOI] [PubMed] [Google Scholar]
  18. Spiegel K., Pasternak G. W. Meptazinol: a novel Mu-1 selective opioid analgesic. J Pharmacol Exp Ther. 1984 Feb;228(2):414–419. [PubMed] [Google Scholar]
  19. Stephens R. J., Waterfall J. F., Franklin R. A. A review of the biological properties and metabolic disposition of the new analgesic agent, meptazinol. Gen Pharmacol. 1978;9(2):73–78. doi: 10.1016/0306-3623(78)90002-2. [DOI] [PubMed] [Google Scholar]
  20. Strahan S. K., Pleuvry B. J., Modla C. Y. Effect of meptazinol on neuromuscular transmission in the isolated rat phrenic nerve-diaphragm preparation. Br J Anaesth. 1985 Nov;57(11):1095–1099. doi: 10.1093/bja/57.11.1095. [DOI] [PubMed] [Google Scholar]
  21. WILSON I. B., HATCH M. A., GINSBURG S. Carbamylation of acetvlcholinesterase. J Biol Chem. 1960 Aug;235:2312–2315. [PubMed] [Google Scholar]
  22. Wali F. A. On the cholinergic component of action of meptazinol. Acta Physiol Pharmacol Latinoam. 1986;36(1):77–87. [PubMed] [Google Scholar]

Articles from British Journal of Pharmacology are provided here courtesy of The British Pharmacological Society

RESOURCES